P3.02b-112 Feasibility of Re-Biopsy in Patients with Non-Small Cell Lung Cancer after Failure of Epidermal Growth Factor Receptor Targeted Therapy

Abstract

Afatinib 2.) Use Anti-PI3K or mTOR-inhibitor such as Torisel 20 mg IV weekly.Results: 21 cases of T790M activating mutation came from: 1.) 22 cases of classical exon 19 deletion had 5 cases of T790M 2.) 7 cases of exon 21 point mutation had 6 cases of T790M 3.) 13 cases of various exon 19 mutation had 10 cases of T790M All 21 cases of T790M survived the resistance treatment at least 1 year after the discovery T790M. Conclusion: Our results appeared to show; 1.) Multiple targeted medicines treatment appeared to reduce the resistance to TKI 2.) Those harbored classical exon 19 deletion appeared to have less TKI resistance 3.) Those harbored exon 21 EGFR mutation and non-classical exon 19 mutation appeared to have TKI resistance more (average 1 year) 4).We could avoid using chemotherapy in those who developed TKI resistance at least in a short period of time and it will require further study.